{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:25:27Z","timestamp":1792013127543,"version":"4.4.0"},"reference-count":233,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bioorg.2024.107930","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T06:51:22Z","timestamp":1730271082000},"page":"107930","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Combretastatin A-4 based compounds as potential anticancer agents: A review"],"prefix":"10.1016","volume":"153","author":[{"given":"Mai H.","family":"Omar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soha H.","family":"Emam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demiana S.","family":"Mikhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salwa","family":"Elmeligie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2024.107930_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103565","article-title":"Emerging role of exosomes as biomarkers in cancer treatment and diagnosis","volume":"169","author":"Hanjani","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bioorg.2024.107930_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2019.109849","article-title":"Small molecular target-based multifunctional upconversion nanocomposites for targeted and in-depth photodynamic and chemo-anticancer therapy","volume":"104","author":"Jia","year":"2019","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.bioorg.2024.107930_b0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1158\/1535-7163.MCT-13-0791","article-title":"Targeting microtubules by natural agents for cancer therapy","volume":"13","author":"Mukhtar","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2024.107930_b0020","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.3390\/cancers13225650","article-title":"Microtubule targeting agents in disease: classic drugs, novel roles","volume":"13","author":"Wordeman","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2024.107930_b0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-3-319-57127-0_5","article-title":"The elephant in the room: The role of microtubules in cancer","volume":"1002","author":"Cirillo","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.bioorg.2024.107930_b0030","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.3390\/molecules25112560","article-title":"Combretastatins: an overview of structure, probable mechanisms of action and potential applications","volume":"25","author":"Karatoprak","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2024.107930_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2021.108940","article-title":"Inhibition of microtubule assembly and cytotoxic effect of graphene oxide on human colorectal carcinoma cell HCT116","volume":"708","author":"Bera","year":"2021","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bioorg.2024.107930_b0040","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.tcb.2018.05.001","article-title":"Microtubule-targeting agents: strategies to hijack the cytoskeleton","volume":"28","author":"Steinmetz","year":"2018","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bioorg.2024.107930_b0045","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1016\/j.bmc.2014.02.035","article-title":"Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function","volume":"22","author":"Field","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115085","article-title":"Discovery and biological evaluation of 4,6-pyrimidine analogues with potential anticancer agents as novel colchicine binding site inhibitors","volume":"248","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0055","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1021\/acs.jnatprod.9b00105","article-title":"Microtubule-targeting drugs: more than antimitotics","volume":"82","author":"Kaul","year":"2019","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bioorg.2024.107930_b0060","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41419-020-2567-0","article-title":"Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment","volume":"11","author":"Serpico","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2024.107930_b0065","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.drudis.2013.10.022","article-title":"Interphase microtubules: chief casualties in the war on cancer?","volume":"19","author":"Ogden","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2024.107930_b0070","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/187152012800228841","article-title":"Tubulin-based structure-affinity relationships for antimitotic Vinca alkaloids","volume":"12","author":"Coderch","year":"2012","journal-title":"Anticancer Agents Med Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105486","article-title":"Discovery of novel tubulin inhibitors targeting the colchicine binding site via virtual screening, structural optimization and antitumor evaluation","volume":"118","author":"Liu","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0080","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jmb.2017.01.001","article-title":"Insights into the distinct mechanisms of action of taxane and non-taxane microtubule stabilizers from cryo-EM structures","volume":"429","author":"Kellogg","year":"2017","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bioorg.2024.107930_b0085","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chembiol.2004.03.028","article-title":"The anticancer natural product pironetin selectively targets Lys352 of \u03b1-tubulin","volume":"11","author":"Usui","year":"2004","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107930_b0090","doi-asserted-by":"crossref","first-page":"12103","DOI":"10.1038\/ncomms12103","article-title":"Pironetin reacts covalently with cysteine-316 of \u03b1-tubulin to destabilize microtubule","volume":"7","author":"Yang","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2024.107930_b0095","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1021\/ci1002894","article-title":"The assembly-inducing laulimalide\/peloruside A binding site on tubulin: molecular modeling and biochemical studies with [3H]peloruside A","volume":"50","author":"Nguyen","year":"2010","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2024.107930_b0100","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/07391102.2015.1078115","article-title":"Analysis of the binding mode of laulimalide to microtubules: Establishing a laulimalide\u2013tubulin pharmacophore","volume":"34","author":"Churchill","year":"2016","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2024.107930_b0105","doi-asserted-by":"crossref","unstructured":"R. Hanna, D.R. Maass, P.H. Atkinson, P.T. Northcote, P.H. Teesdale-Spittle, D.S. Bellows, J.H. Miller, Characterizing the laulimalide-peloruside binding site using site-directed mutagenesis of TUB2 in S. cerevisiae, Mol. Biosyst. 10 (2014) 110\u2013116. https:\/\/doi.org\/10.1039\/c3mb70380k.","DOI":"10.1039\/C3MB70380K"},{"key":"10.1016\/j.bioorg.2024.107930_b0110","doi-asserted-by":"crossref","first-page":"13817","DOI":"10.1073\/pnas.1408124111","article-title":"A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs","volume":"111","author":"Prota","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2024.107930_b0115","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2021847118","article-title":"Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site","volume":"118","author":"Matthew","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2024.107930_b0120","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg4168","article-title":"Cevipabulin-tubulin complex reveals a novel agent binding site on \u03b1-tubulin with tubulin degradation effect","volume":"7","author":"Yang","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioorg.2024.107930_b0125","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1039\/C9RA10094F","article-title":"Design, eco-friendly synthesis, molecular modeling and anticancer evaluation of thiazol-5(4H)-ones as potential tubulin polymerization inhibitors targeting the colchicine binding site","volume":"10","author":"El-Naggar","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2024.107930_b0130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.canlet.2017.05.016","article-title":"BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549\/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe","volume":"402","author":"Bai","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2024.107930_b0135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1124\/mol.118.114801","article-title":"Colchicine binding site agent DJ95 overcomes drug resistance and exhibits antitumor efficacy","volume":"96","author":"Arnst","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107930_b0140","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/sj.bjc.6605489","article-title":"Class III \u03b2-tubulin expression and in vitro resistance to microtubule targeting agents","volume":"102","author":"Stengel","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2024.107930_b0145","doi-asserted-by":"crossref","first-page":"10298","DOI":"10.1038\/s41598-017-10972-0","article-title":"Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function","volume":"7","author":"Lindamulage","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2024.107930_b0150","first-page":"49","article-title":"Molecular, biological and content studies on Colchicum L. species","volume":"1","author":"Ozcakir","year":"2021","journal-title":"Nat. Pro. Biotech."},{"key":"10.1016\/j.bioorg.2024.107930_b0155","doi-asserted-by":"crossref","first-page":"10067","DOI":"10.1021\/bi00089a023","article-title":"Thermodynamics of ligand-induced assembly of tubulin","volume":"32","author":"D\u00edaz","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioorg.2024.107930_b0160","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2174\/1381612013397438","article-title":"Physiochemical aspects of tubulin-interacting antimitotic drugs","volume":"7","author":"Correia","year":"2001","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bioorg.2024.107930_b0165","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/med.20242","article-title":"Drugs that target dynamic microtubules: a new molecular perspective","volume":"31","author":"Stanton","year":"2011","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2024.107930_b0170","doi-asserted-by":"crossref","first-page":"10192","DOI":"10.1158\/0008-5472.CAN-10-2429","article-title":"Free tubulin modulates mitochondrial membrane potential in cancer cells","volume":"70","author":"Maldonado","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107930_b0175","doi-asserted-by":"crossref","unstructured":"V.D. Ravichandra, C. Ramesh, M.K. Swamy, B. Purushotham, G.R. Rudramurthy, Anticancer Plants: chemistry, pharmacology, and potential applications, in: M.S. Akhtar, M.K. Swamy (Eds.), Anticancer Plants Prop. Appl., Springer Singapore, 2018: pp. 485\u2013515. https:\/\/doi.org\/10.1007\/978-981-10-8548-2.","DOI":"10.1007\/978-981-10-8548-2_21"},{"key":"10.1016\/j.bioorg.2024.107930_b0180","first-page":"665","article-title":"VDAC in cancer","volume":"2017","author":"Mazure","year":"1858","journal-title":"Biochim. Biophys. Acta - Bioenerg."},{"key":"10.1016\/j.bioorg.2024.107930_b0185","first-page":"68","article-title":"Anticancer effects of clinically acceptable colchicine concentrations on human gastric cancer cell lines, Kaohsiung","volume":"32","author":"Lin","year":"2016","journal-title":"J. Med. Sci."},{"key":"10.1016\/j.bioorg.2024.107930_b0190","first-page":"892","article-title":"Colchicine semisynthetics: chemotherapeutics for cancer?","volume":"20","author":"Sivakumar","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0195","first-page":"63","article-title":"Synthesis and cytotoxic activity of certain diaryl cyclohexene derivatives structurally related to combretastatins","volume":"3","author":"Abd El Hameid","year":"2013","journal-title":"Int. J. Med. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2024.107930_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.07.048","article-title":"Synthesis and biological evaluation of cis-restrained carbocyclic combretastatin A-4 analogs: Influence of the ring size and saturation on cytotoxic properties","volume":"27","author":"Nowikow","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0205","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.2174\/1381612825666190111123959","article-title":"Cytotoxic stilbenes and derivatives as promising antimitotic leads for cancer therapy","volume":"24","author":"Faustino","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bioorg.2024.107930_b0210","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF01954881","article-title":"Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4","volume":"45","author":"Pettit","year":"1989","journal-title":"Experientia"},{"key":"10.1016\/j.bioorg.2024.107930_b0215","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1021\/acs.jnatprod.7b01062","article-title":"Synthesis and in vitro bioactivity of polyunsaturated fatty acid conjugates of combretastatin A-4","volume":"81","author":"Ojike","year":"2018","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bioorg.2024.107930_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2020.128025","article-title":"Synthesis, biological evaluation, and modeling studies of 1,3-disubstituted cyclobutane-containing analogs of combretastatin A4","volume":"1210","author":"Malashchuk","year":"2020","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2024.107930_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127923","article-title":"Novel pyrazolo[4,3-d]pyrimidine microtubule targeting agents (MTAs): Synthesis, structure\u2013activity relationship, in vitro and in vivo evaluation as antitumor agents","volume":"41","author":"Islam","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107930_b0230","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12032-021-01615-6","article-title":"Novel molecules as the emerging trends in cancer treatment: an update","volume":"39","author":"Sekar","year":"2022","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bioorg.2024.107930_b0235","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.pharep.2016.08.007","article-title":"Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status","volume":"68","author":"Jaroch","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bioorg.2024.107930_b0240","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.chempr.2016.12.005","article-title":"Structural basis of cis- and trans-combretastatin binding to tubulin","volume":"2","author":"Gaspari","year":"2017","journal-title":"Chem"},{"key":"10.1016\/j.bioorg.2024.107930_b0245","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/cmdc.201800641","article-title":"Synthesis, biological evaluation, and molecular docking of combretastatin and colchicine derivatives and their hCE1-activated prodrugs as antiviral agents","volume":"14","author":"Richter","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2024.107930_b0250","first-page":"4638","article-title":"Design, synthesis and docking based studies of combretastatin analog as anti-cancer activity","volume":"07","author":"Tiwari","year":"2020","journal-title":"Eur. J. Mol. Clin. Med."},{"key":"10.1016\/j.bioorg.2024.107930_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13765-019-0434-4","article-title":"Synthesis and anticancer activities of polymethylenedioxy analogues of combretastatin A-2","volume":"62","author":"Kwak","year":"2019","journal-title":"Appl. Biol. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0260","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.3390\/pharmaceutics14061191","article-title":"Synthesis and biological evaluation of highly active 7-anilino triazolopyrimidines as potent antimicrotubule agents","volume":"14","author":"Oliva","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2024.107930_b0265","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1039\/D2MD00144F","article-title":"An organometallic analogue of combretastatin A-4 and its apoptosis-inducing effects on lymphoma, leukemia and other tumor cells in vitro","volume":"13","author":"Onambele","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0270","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejmech.2016.04.045","article-title":"Combretastatin A-4 derived 5-(1-methyl-4-phenyl-imidazol-5-yl)indoles with superior cytotoxic and anti-vascular effects on chemoresistant cancer cells and tumors","volume":"118","author":"Mahal","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0275","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202201206","article-title":"New combretastatin analogs as anticancer agents: design, synthesis, microtubules polymerization inhibition, and molecular docking Studies","volume":"20","author":"Abdul Hussein","year":"2023","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.bioorg.2024.107930_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114738","article-title":"Discovery of a novel piperlongumine analogue as a microtubule polymerization inhibitor with potent anti-angiogenic and anti-metastatic efficacy","volume":"243","author":"Qin","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0285","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/cmdc.201700045","article-title":"Anticancer activity of stilbene-based derivatives","volume":"12","author":"De Filippis","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2024.107930_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113058","article-title":"Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1\/PD-L1 interaction for cancer treatment","volume":"213","author":"Yang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0295","doi-asserted-by":"crossref","first-page":"13082","DOI":"10.3390\/ijms222313082","article-title":"Imidazole analogs of vascular-disrupting combretastatin A-4 with pleiotropic efficacy against resistant colorectal cancer models","volume":"22","author":"Reipsch","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107930_b0300","doi-asserted-by":"crossref","first-page":"25387","DOI":"10.1038\/srep25387","article-title":"Design, synthesis and antitumor activity of novel link-bridge and B-ring modified combretastatin A-4 (CA-4) analogues as potent antitubulin agents","volume":"6","author":"Duan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2024.107930_b0305","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1134\/S1068162015010033","article-title":"Synthesis of new combretastatin A-4 analogues and study of their anti-inflammatory activity","volume":"41","author":"Davydova","year":"2015","journal-title":"Russ. J. Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0310","doi-asserted-by":"crossref","first-page":"687","DOI":"10.20546\/ijcmas.2018.701.084","article-title":"Quantification, antibacterial assay and cytotoxic effect of combretastatin, an anticancer compound from three Indian Combretum species","volume":"7","author":"Das","year":"2018","journal-title":"Int. J. Curr. Microbiol. Appl. Sci."},{"key":"10.1016\/j.bioorg.2024.107930_b0315","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/13543776.2019.1651841","article-title":"Combretastatin-based compounds with therapeutic characteristics: a patent review","volume":"29","author":"Nainwal","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2024.107930_b0320","first-page":"1051","article-title":"Synthesis and biological evaluation of combretastatin A-4 and three combretastatin-based hybrids","volume":"7","author":"Gonz\u00e1lez","year":"2012","journal-title":"Nat. Prod. Commun."},{"key":"10.1016\/j.bioorg.2024.107930_b0325","doi-asserted-by":"crossref","first-page":"9754","DOI":"10.1021\/acsomega.8b00996","article-title":"Combretastatin-inspired heterocycles as antitubulin anticancer agents","volume":"3","author":"Hura","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2024.107930_b0330","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/thy.2008.0321","article-title":"A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome","volume":"19","author":"Mooney","year":"2009","journal-title":"Thyroid"},{"key":"10.1016\/j.bioorg.2024.107930_b0335","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1158\/1078-0432.CCR-11-2414","article-title":"Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors","volume":"18","author":"Patterson","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107930_b0340","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1038\/bjc.2012.165","article-title":"Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial","volume":"106","author":"Cummings","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2024.107930_b0345","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3390\/cancers12010074","article-title":"A phase 1B clinical study of combretastatin A1 diphosphate (OXi4503) and cytarabine (ARA-C) in combination (OXA) for patients with relapsed or refractory acute myeloid leukemia","volume":"12","author":"Uckun","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2024.107930_b0350","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00280-014-2388-x","article-title":"An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors","volume":"73","author":"Murakami","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107930_b0355","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1038\/bjc.2014.137","article-title":"A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours","volume":"110","author":"Eskens","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2024.107930_b0360","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(15)70102-6","article-title":"Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Blay","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2024.107930_b0365","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215336","article-title":"Sabizabulin, a potent orally bioavailable colchicine binding site agent, suppresses HER2+ breast cancer and metastasis","volume":"14","author":"Krutilina","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2024.107930_b0370","unstructured":"Veru, Oral sabizabulin reduces mortality in hospitalized COVID-19 patients with at high risk for ARDS, (2022) (accessed July 17,2024). https:\/\/ir.verupharma.com\/news-events\/press-releases\/detail\/152\/veru-announces-presentation-of-phase-3-study-of-sabizabulin."},{"key":"10.1016\/j.bioorg.2024.107930_b0375","article-title":"Audio Interview: Caring for hospitalized patients with covid-19","volume":"387","author":"Rubin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2024.107930_b0380","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1007\/s00044-022-02969-w","article-title":"Synthesis, characterization and biological activities of nitrogen-containing Combretastatin A-4 derivatives","volume":"31","author":"Tang","year":"2022","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2024.107930_b0385","doi-asserted-by":"crossref","first-page":"6787","DOI":"10.2174\/0929867326666191003154051","article-title":"Tubulin inhibitors binding to colchicine-site: a review from 2015 to 2019","volume":"27","author":"Xia","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0390","first-page":"6491","article-title":"Combretastatins: potential tubulin inhibitors","volume":"20","author":"Chawla","year":"2022","journal-title":"NeuroQuantology"},{"key":"10.1016\/j.bioorg.2024.107930_b0395","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.canlet.2017.06.032","article-title":"Suppression of angiogenesis and tumour progression by combretastatin and derivatives","volume":"403","author":"Sherbet","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2024.107930_b0400","doi-asserted-by":"crossref","first-page":"19018","DOI":"10.18632\/oncotarget.7968","article-title":"ZLM-7 exhibits anti-angiogenic effects via impaired endothelial cell function and blockade of VEGF\/VEGFR-2 signaling","volume":"7","author":"Su","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2024.107930_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.134437","article-title":"Design, synthesis, characterization, antioxidant, antiproliferative activity and molecular docking studies of new transition metal complexes of 1,2,4-triazole as combretastatin A-4 analogues","volume":"1274","author":"Jawad","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2024.107930_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114817","article-title":"Novel combretastatin A-4 derivative containing aminophosphonates as dual inhibitors of tubulin and matrix metalloproteinases for lung cancer treatment","volume":"244","author":"Huang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0415","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.3390\/molecules27144621","article-title":"Synthesis and biological activity screening of newly synthesized trimethoxyphenyl-based analogues as potential anticancer agents","volume":"27","author":"Al-Warhi","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2024.107930_b0420","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2174\/1389450124666230731094837","article-title":"Microtubules and cell division: Potential pharmacological targets in cancer therapy","volume":"24","author":"Sebastian","year":"2023","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bioorg.2024.107930_b0425","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/med.21568","article-title":"Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy","volume":"39","author":"Arnst","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2024.107930_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114977","article-title":"Not all benzimidazole derivatives are microtubule destabilizing agents","volume":"164","author":"Song","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2024.107930_b0435","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1039\/C5OB02005K","article-title":"Photoswitchable anticancer activity via trans-cis isomerization of a combretastatin A-4 analog","volume":"14","author":"Sheldon","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0440","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1039\/c1cs15023e","article-title":"Azobenzene photoswitches for biomolecules","volume":"40","author":"Beharry","year":"2011","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bioorg.2024.107930_b0445","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1039\/tf9534900735","article-title":"The absorption spectra of azobenzene and some derivatives","volume":"49","author":"Birnbaum","year":"1953","journal-title":"Trans. Faraday Soc."},{"key":"10.1016\/j.bioorg.2024.107930_b0450","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/S0960-894X(97)10044-0","article-title":"Site-specific incorporation of photoisomerizable azobenzene groups into ribonuclease S","volume":"7","author":"Liu","year":"1997","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107930_b0455","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.biopha.2016.01.040","article-title":"2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol (SQ0814061), a novel microtubule inhibitor, evokes G2\/M cell cycle arrest and apoptosis in human breast cancer cells","volume":"78","author":"Xu","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2024.107930_b0460","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1021\/jm970644q","article-title":"Antineoplastic agents. 379. Synthesis of phenstatin phosphate","volume":"41","author":"Pettit","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0465","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/bs.acr.2017.07.007","article-title":"Selenocompounds in cancer therapy: an overview","volume":"136","author":"Bartolini","year":"2017","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107930_b0470","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s12272-016-0849-y","article-title":"Synthesis and cytotoxic activity of certain trisubstituted azetidin-2-one derivatives as a cis-restricted combretastatin A-4 analogues","volume":"40","author":"Elmeligie","year":"2017","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.bioorg.2024.107930_b0475","series-title":"Green Approaches in Medicinal Chemistry for Sustainable Drug Design","first-page":"861","article-title":"Microwave-induced synthesis as a part of green chemistry approach for novel antiinflammatory agents","author":"Panda","year":"2020"},{"key":"10.1016\/j.bioorg.2024.107930_b0480","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.ejmech.2016.10.051","article-title":"Design, synthesis, and biological evaluation of novel alkylsulfanyl-1,2,4-triazoles as cis-restricted combretastatin A-4 analogues","volume":"125","author":"Li","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0485","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1021\/jm061142s","article-title":"Highly potent triazole-based tubulin polymerization inhibitors","volume":"50","author":"Zhang","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0490","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1021\/acscombsci.5b00024","article-title":"One-pot parallel synthesis of alkyl sulfides, sulfoxides, and sulfones","volume":"17","author":"Bogolubsky","year":"2015","journal-title":"ACS Comb. Sci."},{"key":"10.1016\/j.bioorg.2024.107930_b0495","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ejmech.2017.12.004","article-title":"Design, synthesis, biological evaluation and cocrystal structures with tubulin of chiral \u03b2-lactam bridged combretastatin A-4 analogues as potent antitumor agents","volume":"144","author":"Zhou","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0500","doi-asserted-by":"crossref","first-page":"10329","DOI":"10.1021\/acs.jmedchem.6b01268","article-title":"Potent antitumor activities and structure basis of the chiral \u03b2-lactam bridged analogue of combretastatin A-4 binding to tubulin","volume":"59","author":"Zhou","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111577","article-title":"Design, synthesis and biological evaluation of novel vicinal diaryl-substituted 1H-Pyrazole analogues of combretastatin A-4 as highly potent tubulin polymerization inhibitors","volume":"181","author":"Romagnoli","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2019.02.049","article-title":"Synthesis and bioevaluation of diarylpyrazoles as antiproliferative agents","volume":"171","author":"Wang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111697","article-title":"Potent combretastatin A-4 analogs containing 1,2,4-triazole: Synthesis, antiproliferative, anti-tubulin activity, and docking study","volume":"183","author":"Mustafa","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0520","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1021\/jm100245q","article-title":"Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogues","volume":"53","author":"Romagnoli","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103260","article-title":"Novel [1,2,4]triazolo[1,5-a]pyrimidine derivatives as potent antitubulin agents: Design, multicomponent synthesis and antiproliferative activities","volume":"92","author":"Yang","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0530","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.bmcl.2018.05.020","article-title":"Synthesis, characterization and cytotoxicity studies of 1,2,3-triazoles and 1,2,4-triazolo [1,5-a] pyrimidines in human breast cancer cells","volume":"28","author":"Gilandoust","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107930_b0535","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3390\/ph13110393","article-title":"Potent quinoline-containing combretastatin A-4 analogues: design, synthesis, antiproliferative, and anti-tubulin activity","volume":"13","author":"Ibrahim","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2024.107930_b0540","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.isci.2019.10.003","article-title":"Structural basis of colchicine-site targeting acylhydrazones active against multidrug-resistant acute lymphoblastic leukemia","volume":"21","author":"Cury","year":"2019","journal-title":"Iscience"},{"key":"10.1016\/j.bioorg.2024.107930_b0545","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ejmech.2017.07.040","article-title":"Design, synthesis and biological evaluation of 4-anilinoquinoline derivatives as novel potent tubulin depolymerization agents","volume":"138","author":"Zhou","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104076","article-title":"Synthesis and biological evaluation of benzofuran-based 3,4,5-trimethoxybenzamide derivatives as novel tubulin polymerization inhibitors","volume":"102","author":"Li","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0555","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.1021\/jm200454y","article-title":"Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties","volume":"54","author":"Flynn","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0560","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/15384047.2016.1139245","article-title":"Rapid induction of apoptosis in chronic lymphocytic leukemia cells by the microtubule disrupting agent BNC105","volume":"17","author":"Bates","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bioorg.2024.107930_b0565","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1021\/acs.jmedchem.5b00155","article-title":"Design, synthesis, in vitro, and in vivo anticancer and antiangiogenic activity of novel 3-arylaminobenzofuran derivatives targeting the colchicine site on tubulin","volume":"58","author":"Romagnoli","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112625","article-title":"Synthesis, and biological evaluation of 3,6-diaryl-[1,2,4]triazolo[4,3-a]pyridine analogues as new potent tubulin polymerization inhibitors","volume":"204","author":"Yang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0575","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1021\/acsmedchemlett.6b00252","article-title":"Synthesis and bioevaluation of 3,6-diaryl-[1,2,4]triazolo[4,3-b] pyridazines as antitubulin agents","volume":"7","author":"Xu","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107930_b0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114864","article-title":"Rational design, synthesis and biological evaluation of novel 2-(substituted amino)-[1,2,4]triazolo[1,5-a]pyrimidines as novel tubulin polymerization inhibitors","volume":"244","author":"Chen","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0585","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1080\/14756366.2022.2130284","article-title":"Design, synthesis and biological evaluation of novel diarylpyridine derivatives as tubulin polymerisation inhibitors","volume":"37","author":"Yang","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0590","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1021\/jm500002k","article-title":"Design, synthesis, and biological evaluation of novel pyridine-bridged analogues of combretastatin-A4 as anticancer agents","volume":"57","author":"Zheng","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0595","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3390\/ph15091044","article-title":"Synthesis, characterisation and mechanism of action of anticancer 3-fluoroazetidin-2-ones","volume":"15","author":"Malebari","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2024.107930_b0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112050","article-title":"\u03b2-Lactams with antiproliferative and antiapoptotic activity in breast and chemoresistant colon cancer cells","volume":"189","author":"Malebari","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0605","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3892\/ol.2015.3867","article-title":"Effect of CPU-XT-008, a combretastatin A-4 analogue, on the proliferation, apoptosis and expression of vascular endothelial growth factor and basic fibroblast growth factor in human umbilical vein endothelial cells","volume":"11","author":"Xiong","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bioorg.2024.107930_b0610","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.1016\/j.bmc.2013.07.028","article-title":"Synthesis and biological evaluation of indole-based, anti-cancer agents inspired by the vascular disrupting agent 2-(3\u2032-hydroxy-4\u2032-methoxyphenyl)-3-(3\u2033,4\u2033,5\u2033-trimethoxybenzoyl)-6-methoxyindole (OXi8006)","volume":"21","author":"MacDonough","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173692","article-title":"Vascular disrupting agents in cancer therapy","volume":"891","author":"Smolarczyk","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107930_b0620","doi-asserted-by":"crossref","first-page":"14721","DOI":"10.1002\/jcp.28230","article-title":"Targeted-nanoliposomal combretastatin A4 (CA-4) as an efficient antivascular candidate in the metastatic cancer treatment","volume":"234","author":"Nik","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bioorg.2024.107930_b0625","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.vph.2016.05.006","article-title":"Vascular disrupting activity of combretastatin analogues","volume":"83","author":"Porc\u00f9","year":"2016","journal-title":"Vasc.Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107930_b0630","doi-asserted-by":"crossref","unstructured":"R. Romagnoli, P.G. Baraldi, M.D. Carrion, O. Cruz-Lopez, C. Lopez Cara, G. Basso, G. Viola, M. Khedr, J. Balzarini, S. Mahboobi, A. Sellmer, A. Brancale, E. Hamel, 2-Arylamino-4-amino-5-aroylthiazoles. \u201cOne-Pot\u201d synthesis and biological evaluation of a new class of inhibitors of tubulin polymerization, J. Med. Chem. 52 (2009) 5551\u20135555. https:\/\/doi.org\/10.1021\/jm9001692.","DOI":"10.1021\/jm9001692"},{"key":"10.1016\/j.bioorg.2024.107930_b0635","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1021\/jm2013979","article-title":"Synthesis and evaluation of 1,5-disubstituted tetrazoles as rigid analogues of combretastatin A-4 with potent antiproliferative and antitumor activity","volume":"55","author":"Romagnoli","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0640","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1016\/j.ejmech.2008.12.018","article-title":"A diaryl sulfide, sulfoxide, and sulfone bearing structural similarities to combretastatin A-4","volume":"44","author":"Barbosa","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0645","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1016\/j.bmcl.2013.06.009","article-title":"Synthesis and evaluation of diaryl sulfides and diaryl selenide compounds for antitubulin and cytotoxic activity","volume":"23","author":"dos dos Santos","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107930_b0650","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3390\/molecules25030660","article-title":"Synthesis of Combretastatin A-4 and 3\u2019-aminocombretastatin A-4 derivatives with aminoacid containing pendants and study of their interaction with tubulin and as downregulators of the VEGF, hTERT and c-myc gene expression","volume":"25","author":"Agut","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2024.107930_b0655","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1021\/jm060616k","article-title":"2-Amino and 2\u2018-Aminocombretastatin derivatives as potent antimitotic agents","volume":"49","author":"Chang","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2020.109202","article-title":"2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol (SQ) inhibits cancer cell metastasis behavior of TNBC via suppressing EMT and VEGF","volume":"329","author":"Zheng","year":"2020","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2024.107930_b0665","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3389\/fonc.2019.01370","article-title":"Role of matrix metalloproteinases in angiogenesis and cancer","volume":"9","author":"Quintero-Fabi\u00e1n","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2024.107930_b0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112260","article-title":"Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview","volume":"194","author":"Mondal","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0675","first-page":"82","article-title":"Role of \u03b1-tubulin acetylation and protein kinase D2 Ser\/Tyr phosphorylation in modulation by ghrelin of Porphyromonas gingivalis-induced enhancement in matrix metalloproteinase-9 (MMP-9) secretion by salivary gland cells","volume":"04","author":"Slomiany","year":"2016","journal-title":"J. Biosci. Med."},{"key":"10.1016\/j.bioorg.2024.107930_b0680","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.2174\/092986711795471329","article-title":"Recent advances in studies on hydroxamates as matrix metalloproteinase inhibitors: a review","volume":"18","author":"Yadav","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115985","article-title":"Synthesis and bioevaluation of N-(3,4,5-trimethoxyphenyl)-1H-pyrazolo [3,4-b]pyridin-3-amines as tubulin polymerization inhibitors with anti-angiogenic effects","volume":"31","author":"Hao","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0690","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1021\/jm101027s","article-title":"Scaffold-hopping strategy: Synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents","volume":"54","author":"Tung","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0695","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1021\/jm200587f","article-title":"Remarkable potential of the \u03b1-aminophosphonate\/phosphinate structural motif in medicinal chemistry","volume":"54","author":"Mucha","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112067","article-title":"Synthesis, mechanisms of action, and toxicity of novel aminophosphonates derivatives conjugated irinotecan in vitro and in vivo as potent antitumor agents","volume":"189","author":"Huang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0705","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mrrev.2008.02.004","article-title":"Epigenetic interplay between histone modifications and DNA methylation in gene silencing","volume":"659","author":"Vaissi\u00e8re","year":"2008","journal-title":"Mutat. Res. Mutat. Res."},{"key":"10.1016\/j.bioorg.2024.107930_b0710","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1615\/CritRevOncog.2015012997","article-title":"Histone deacetylases and mechanisms of regulation of gene expression (Histone deacetylases in cancer)","volume":"20","author":"Chen","year":"2015","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.bioorg.2024.107930_b0715","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.molonc.2012.07.003","article-title":"Histone deacetylases and cancer","volume":"6","author":"Barneda Zahonero","year":"2012","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bioorg.2024.107930_b0720","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/bjc.2016.36","article-title":"Inhibition of histone deacetylases in cancer therapy: Lessons from leukaemia","volume":"114","author":"Ceccacci","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2024.107930_b0725","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","article-title":"Histone deacetylases and cancer","volume":"26","author":"Glozak","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2024.107930_b0730","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2024.107930_b0735","first-page":"140","article-title":"Histone deacetylase inhibitors: An overview of the clinical studies in solid tumors, Anticancer","volume":"25","author":"Slingerland","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2024.107930_b0740","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: Achieving the full therapeutic potential of HDACi","volume":"8","author":"Suraweera","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2024.107930_b0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113790","article-title":"Discovery of novel tubulin\/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency","volume":"225","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0750","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2227","article-title":"Vorinostat","volume":"6","author":"Grant","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2024.107930_b0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106112","article-title":"Discovery of a 2,6-diarylpyridine-based hydroxamic acid derivative as novel histone deacetylase 8 and tubulin dual inhibitor for the treatment of neuroblastoma","volume":"128","author":"Tang","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115529","article-title":"Synthesis and bioevaluation of novel stilbene-based derivatives as tubulin\/HDAC dual-target inhibitors with potent antitumor activities in vitro and in vivo","volume":"257","author":"Zhu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0765","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ejmech.2016.11.012","article-title":"Design, synthesis and anticancer properties of IsoCombretaQuinolines as potent tubulin assembly inhibitors","volume":"127","author":"Khelifi","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0770","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1021\/jm900321u","article-title":"Isocombretastatins A versus combretastatins A: The forgotten isoCA-4 isomer as a highly promising cytotoxic and antitubulin agent","volume":"52","author":"Messaoudi","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0775","article-title":"Detection of mitochondria membrane potential to study CLIC4 knockdown-induced HN4 cell apoptosis in vitro","volume":"137","author":"Lu","year":"2018","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.bioorg.2024.107930_b0780","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bioorg.2018.02.027","article-title":"Synthesis and biological evaluation of pyrimidine bridged combretastatin derivatives as potential anticancer agents and mechanistic studies","volume":"78","author":"Kumar","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0785","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.canlet.2016.06.020","article-title":"Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt\/\u03b2-catenin pathway","volume":"380","author":"Mao","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2024.107930_b0790","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1021\/acs.bioconjchem.6b00353","article-title":"Combretastatin A-4 analogue: a dual-targeting and tubulin inhibitor containing antitumor Pt(IV) moiety with a unique mode of action","volume":"27","author":"Huang","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0795","doi-asserted-by":"crossref","first-page":"9326","DOI":"10.1021\/ic501446b","article-title":"A new entry to asymmetric platinum(IV) complexes via oxidative chlorination","volume":"53","author":"Ravera","year":"2014","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0800","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1021\/jm101388d","article-title":"Synthesis and biological evaluation of 2,4,5-substituted pyrimidines as a new class of tubulin polymerization inhibitors","volume":"54","author":"Xie","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0805","article-title":"Discovery of novel 1,2,4-triazine-chalcone hybrids as anti-gastric cancer agents via an axis of ROS-ERK-DR5 in vitro and in vivo","volume":"15","author":"Liu","year":"2022","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0810","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ardp.201400096","article-title":"Synthesis, cytotoxicity, docking study, and tubulin polymerization inhibitory activity of novel 1-(3,4-dimethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)- 1H\u20131,2,4-triazole-3-carboxanilides","volume":"347","author":"Aly","year":"2014","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.bioorg.2024.107930_b0815","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1016\/j.ejmech.2010.05.051","article-title":"Design & synthesis of 2-(substituted aryloxy)-5-(substituted benzylidene)-3-phenyl-2,5-dihydro-1H-[1,2,4] triazin-6-one as potential anticonvulsant agents","volume":"45","author":"Kaushik","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112142","article-title":"Reactive oxygen species (ROS) in cancer pathogenesis and therapy: An update on the role of ROS in anticancer action of benzophenanthridine alkaloids","volume":"143","author":"Khan","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2024.107930_b0825","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.semcdb.2017.05.023","article-title":"ROS signalling in the biology of cancer","volume":"80","author":"Moloney","year":"2018","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.bioorg.2024.107930_b0830","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/2467940","article-title":"The roles of ROS in cancer heterogeneity and therapy","volume":"2017","author":"de S\u00e1 Junior","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.bioorg.2024.107930_b0835","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1080\/14756366.2021.1899168","article-title":"Discovery of novel quinoline-based analogues of combretastatin A-4 as tubulin polymerisation inhibitors with apoptosis inducing activity and potent anticancer effect","volume":"36","author":"Ibrahim","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111732","article-title":"Design, synthesis, and biological evaluation of 1-substituted -2-aryl imidazoles targeting tubulin polymerization as potential anticancer agents","volume":"184","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0845","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1016\/j.tetlet.2012.02.110","article-title":"Design and synthesis of 3,5-disubstituted boron-containing 1,2,4-oxadiazoles as potential combretastatin A-4 (CA-4) analogs","volume":"53","author":"Das","year":"2012","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.bioorg.2024.107930_b0850","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/cmdc.200900477","article-title":"Oxazole-bridged combretastatin A analogues with improved anticancer properties","volume":"5","author":"Biersack","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2024.107930_b0855","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/17460441.2017.1319357","article-title":"An overview of quinoline as a privileged scaffold in cancer drug discovery","volume":"12","author":"Musiol","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bioorg.2024.107930_b0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113531","article-title":"Bifunctional chiral selenium-containing 1,4-diarylazetidin-2-ones with potent antitumor activities by disrupting tubulin polymerization and inducing reactive oxygen species production","volume":"221","author":"Tang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0865","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1021\/acs.jmedchem.5b01503","article-title":"Design, synthesis, and biological evaluation of novel selenium (Se-NSAID) molecules as anticancer agents","volume":"59","author":"Plano","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0870","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.1021\/acs.jmedchem.7b00480","article-title":"Design, synthesis, and biological evaluation of novel selenium-containing isocombretastatins and phenstatins as antitumor Agents","volume":"60","author":"Pang","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0875","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1021\/acs.jmedchem.8b00128","article-title":"Synthesis and biological evaluation of selenium-containing 4-anilinoquinazoline derivatives as novel antimitotic agents","volume":"61","author":"An","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0880","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/jcb.30173","article-title":"Review of cancer cell resistance mechanisms to apoptosis and actual targeted therapies","volume":"123","author":"Kulbay","year":"2022","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bioorg.2024.107930_b0885","doi-asserted-by":"crossref","first-page":"148","DOI":"10.21608\/bfpc.2019.101875","article-title":"Snake venom, bee venom and their components exert an anti-cancer effect by triggering apoptosis and cell cycle arrest in prostate cancer","volume":"57","author":"Elrefay","year":"2019","journal-title":"Bull. Fac. Pharmacy, Cairo Univ."},{"key":"10.1016\/j.bioorg.2024.107930_b0890","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10495-020-01649-7","article-title":"The role of the DFF40\/CAD endonuclease in genomic stability","volume":"26","author":"Kulbay","year":"2021","journal-title":"Apoptosis"},{"key":"10.1016\/j.bioorg.2024.107930_b0895","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/cbdd.12738","article-title":"Synthesis and biological evaluation of 1,2,3-triazole tethered pyrazoline and chalcone derivatives","volume":"88","author":"Hussaini","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2024.107930_b0900","doi-asserted-by":"crossref","first-page":"6238","DOI":"10.1016\/j.bmc.2010.07.037","article-title":"Synthesis and in vitro antitumor activity of new 4,5-dihydropyrazole derivatives","volume":"18","author":"Congiu","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0905","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.1016\/j.bmcl.2007.07.105","article-title":"Design, synthesis, and biological testing of pyrazoline derivatives of combretastatin-A4","volume":"17","author":"Johnson","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107930_b0910","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1016\/j.bmc.2008.03.049","article-title":"1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin","volume":"16","author":"Odlo","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0915","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1021\/jm1000979","article-title":"N -((1-benzyl-1H -1,2,3-triazol-4-yl)methyl)arylamide as a new scaffold that provides rapid access to antimicrotubule agents: Synthesis and evaluation of antiproliferative activity against select cancer cell lines","volume":"53","author":"Stefely","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0920","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1002\/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4","article-title":"A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective \u201cligation\u201d of azides and terminal alkynes","volume":"41","author":"Rostovtsev","year":"2002","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bioorg.2024.107930_b0925","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3390\/sym14102088","article-title":"Design, synthesis, and investigation of cytotoxic activity of cis-vinylamide-linked combretastatin analogues as potential anticancer agents","volume":"14","author":"Al-Warhi","year":"2022","journal-title":"Symmetry (Basel)"},{"key":"10.1016\/j.bioorg.2024.107930_b0930","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14756366.2021.1976772","article-title":"A review on synthetic chalcone derivatives as tubulin polymerisation inhibitors","volume":"37","author":"Liu","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0935","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ejps.2012.12.003","article-title":"Overview of the therapeutic potential of piplartine (piperlongumine)","volume":"48","author":"Bezerra","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2024.107930_b0940","doi-asserted-by":"crossref","first-page":"8218","DOI":"10.1016\/j.bmc.2010.10.008","article-title":"Synthesis, molecular modeling and biological evaluation of guanidine derivatives as novel antitubulin agents","volume":"18","author":"Qian","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0945","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.4155\/fmc.09.80","article-title":"Thiosemicarbazones: The new wave in cancer treatment","volume":"1","author":"Kalinowski","year":"2009","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0950","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2024.107930_b0955","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.ejmech.2016.09.013","article-title":"[1,2]Oxazolo[5,4-e]isoindoles as promising tubulin polymerization inhibitors","volume":"124","author":"Span\u00f2","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0960","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1021\/jm701018h","article-title":"4,5-Diarylisoxazole Hsp90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer","volume":"51","author":"Brough","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b0965","unstructured":"M. Caldarelli, I. Beria, N. Colombo, C. Piutti, M. Salsa, G. Traquandi, Isoxazolo-quinazolines as modulators of protein kinase activity, PCT Int. Appl. WO 2012013557 (2012). https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO2012013557."},{"key":"10.1016\/j.bioorg.2024.107930_b0970","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0960-894X(02)00051-3","article-title":"Tricyclic isoxazoles are novel inhibitors of the multidrug resistance protein (MRP1)","volume":"12","author":"Norman","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107930_b0975","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ctrv.2011.10.006","article-title":"Diffuse malignant peritoneal mesothelioma - An update on treatment","volume":"38","author":"Mirarabshahii","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bioorg.2024.107930_b0980","doi-asserted-by":"crossref","first-page":"13119","DOI":"10.18632\/oncotarget.3761","article-title":"Anti-tumor activity of selective inhibitors of XPO1\/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: The role of survivin","volume":"6","author":"De Cesare","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2024.107930_b0985","doi-asserted-by":"crossref","first-page":"10222","DOI":"10.3390\/ijms231810222","article-title":"The new microtubule-targeting agent SIX2G induces immunogenic cell death in multiple myeloma","volume":"23","author":"Grillone","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107930_b0990","doi-asserted-by":"crossref","first-page":"205","DOI":"10.15171\/apb.2019.024","article-title":"Understanding apoptosis and apoptotic pathways targeted cancer therapeutics","volume":"9","author":"Jan","year":"2019","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.bioorg.2024.107930_b0995","doi-asserted-by":"crossref","first-page":"20327","DOI":"10.1073\/pnas.0808036105","article-title":"Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins","volume":"105","author":"Chipuk","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2024.107930_b1000","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/med.21379","article-title":"Direct activation of Bax protein for cancer therapy","volume":"36","author":"Liu","year":"2016","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2024.107930_b1005","doi-asserted-by":"crossref","first-page":"8982","DOI":"10.3390\/ijms24108982","article-title":"Calcium\u2019s role in orchestrating cancer apoptosis: mitochondrial-centric perspective","volume":"24","author":"Moon","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107930_b1010","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/cancers13040624","article-title":"Tumor suppressor protein p53 and inhibitor of apoptosis proteins in colorectal cancer\u2014a promising signaling network for therapeutic interventions","volume":"13","author":"G\u00fcll\u00fcl\u00fc","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2024.107930_b1015","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1177\/0960327117718052","article-title":"Regulation of p53 and survivin by prodigiosin compound derived from Serratia marcescens contribute to caspase-3-dependent apoptosis in acute lymphoblastic leukemia cells","volume":"37","author":"Sam","year":"2018","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.bioorg.2024.107930_b1020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bcp.2017.04.026","article-title":"Identification of novel 1-indolyl acetate-5-nitroimidazole derivatives of combretastatin A-4 as potential tubulin polymerization inhibitors","volume":"137","author":"Yao","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107930_b1025","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1021\/jm010523x","article-title":"Potent, orally active heterocycle-based combretastatin A-4 analogues: Synthesis, structure - activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation","volume":"45","author":"Wang","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b1030","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1158\/0008-5472.CAN-03-3474","article-title":"BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo","volume":"64","author":"Kuo","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107930_b1035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1021\/jm3013097","article-title":"Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors","volume":"56","author":"La Regina","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b1040","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejmech.2014.07.082","article-title":"Discovery and molecular modeling of novel 1-indolyl acetate - 5-Nitroimidazole targeting tubulin polymerization as antiproliferative agents","volume":"85","author":"Duan","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b1045","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/cbin.11340","article-title":"Epidermal growth factor receptor (EGFR) involvement in epithelial-derived cancers and its current antibody-based immunotherapies","volume":"44","author":"London","year":"2020","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.bioorg.2024.107930_b1050","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2024.107930_b1055","article-title":"EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles","volume":"592","author":"da Silva Santos","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bioorg.2024.107930_b1060","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","article-title":"Mechanisms of resistance to EGFR tyrosine kinase inhibitors","volume":"5","author":"Huang","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2024.107930_b1065","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bioorg.2017.12.013","article-title":"Novel 1,2,4-triazole derivatives as potential anticancer agents: Design, synthesis, molecular docking and mechanistic studies","volume":"76","author":"El-Sherief","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b1070","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1021\/jm5008193","article-title":"Synthesis, antimitotic and antivascular activity of 1-(3\u2032,4\u2032,5\u2032-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles","volume":"57","author":"Romagnoli","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b1075","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1158\/0008-5472.CAN-07-0340","article-title":"The role of protein binding in induction of apoptosis by phenethyl isothiocyanate and sulforaphane in human non-small lung cancer cells","volume":"67","author":"Mi","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107930_b1080","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3390\/ph15080913","article-title":"Discovery of putative dual inhibitor of tubulin and EGFR by phenotypic approach on LASSBio-1586 homologs","volume":"15","author":"Barbosa","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2024.107930_b1085","doi-asserted-by":"crossref","first-page":"e85380","DOI":"10.1371\/journal.pone.0085380","article-title":"Docking, synthesis and antiproliferative activity of N-acylhydrazone derivatives designed as combretastatin A4 analogues","volume":"9","author":"Do Amaral","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2024.107930_b1090","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.2174\/1568026619666190808145235","article-title":"Homologation: A versatile molecular modification strategy to drug discovery","volume":"19","author":"Lima","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b1095","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/biomedicines9080872","article-title":"Advances and limitations of antibody drug conjugates for cancer","volume":"9","author":"Mckertish","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.bioorg.2024.107930_b1100","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115534","article-title":"Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy","volume":"421","author":"Best","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107930_b1105","unstructured":"U.S. Food and Drug Administration, (n.d.). https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-chemoimmunotherapy-regimen-patients-relapsed-or-refractory-diffuse-large-b-cell."},{"key":"10.1016\/j.bioorg.2024.107930_b1110","unstructured":"U.S. Food and Drug Administration, (n.d.). https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-padcev."},{"key":"10.1016\/j.bioorg.2024.107930_b1115","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107930_b1120","unstructured":"U.S. Food and Drug Administration, (n.d.). https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approvals-tivdak-tisotumab-vedotin-tftv-recurrent-or-metastatic-cervical."},{"key":"10.1016\/j.bioorg.2024.107930_b1125","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/1538-7445.AM2019-221","article-title":"Tisotumab vedotin induces anti-tumor activity through MMAE-mediated, Fc-mediated, and Fab-mediated effector functions in vitro","volume":"79","author":"Alley","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107930_b1130","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s40265-021-01614-x","article-title":"Disitamab vedotin: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2024.107930_b1135","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1158\/1078-0432.CCR-14-0012","article-title":"FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer","volume":"20","author":"Amiri-Kordestani","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107930_b1140","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1158\/1078-0432.CCR-19-3980","article-title":"FDA approval summary: ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer","volume":"26","author":"Wedam","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2024.107930_b1145","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1021\/jm050355z","article-title":"Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design","volume":"48","author":"Dymock","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107930_b1150","doi-asserted-by":"crossref","first-page":"W357","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2024.107930_b1155","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/bjc.2014.85","article-title":"Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models","volume":"110","author":"Cao","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2024.107930_b1160","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.molcel.2005.03.027","article-title":"AMP-activated protein kinase induces a p53-dependent metabolic checkpoint","volume":"18","author":"Jones","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2024.107930_b1165","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1021\/jm201344a","article-title":"Synthesis and biological evaluation of 1,4-diaryl-2-azetidinones as specific anticancer agents: Activation of adenosine monophosphate activated protein kinase and induction of apoptosis","volume":"55","author":"Tripodi","year":"2012","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824008356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824008356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T21:28:40Z","timestamp":1738186120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824008356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":233,"alternative-id":["S0045206824008356"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107930","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combretastatin A-4 based compounds as potential anticancer agents: A review","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107930","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107930"}}